Use of 18FFDG-PET in patients with suspicion of recurrent differentiated thyroid cancer by elevated antithyroglobulin antibodies levels and negative 131I scan;Uso de la PET-18F-FDG en pacientes con sospecha de recurrencia de cáncer,diferenciado de tiroides por anticuerpos anti-tiroglobulina elevados y, rastreo 131I negativo

Revista Espanola de Medicina Nuclear

Volumn 30, Issue 2, 2011, Pages 77-82

  Sanz Viedma, S ^a   Borrego Dorado, I ^a   Rodriguez Rodriguez J R ^a   Navarro Gonzalez E ^a   Vazquez Albertino R ^a   Fernandez Lopez R ^a   Agudo Martinez A ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

18F fluorodeoxyglucose; Anti thyroglobulin; Positron emission tomography; Thyroid cancer

Indexed keywords

DIURETIC AGENT; FLUORODEOXYGLUCOSE F 18; GLUCOSE; IODINE 131; MUSCLE RELAXANT AGENT; THYROGLOBULIN ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DIAGNOSIS; FEMALE; GLUCOSE BLOOD LEVEL; HISTOLOGY; HUMAN; HYDRATION; MUSCLE; OUTCOME ASSESSMENT; POPULATION; POSITRON EMISSION TOMOGRAPHY; RADIODIAGNOSIS; RADIOGRAPHY; RECURRENT CANCER; RECURRENT DISEASE; THYROID CANCER; THYROID CARCINOMA; THYROIDITIS; WHOLE BODY PET;

ADULT; AUTOANTIBODIES; AUTOANTIGENS; CARCINOMA, PAPILLARY; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; THYROIDITIS, AUTOIMMUNE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79952816806     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/j.remn.2010.10.012     Document Type: Article

References (22)

1. Stokkel M., Duchateao C., Dragoiescu C. The value of FDG-PET in the follow up of differentiated thyroid cáncer: a review of the literature. Q J Nucl Med Mol Imaging. 2006, 50:78-87.
2. Davies L., Weich H.G. Increasing incidence of thyroid cancer in the United States. JAMA. 2006, 295:2164-2167.
3. Pacini F., Mariotti S., Formica N., Elisei R., Anelli S., Capotorti E., et al. Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. Acta Endocrinol. 1988, 119:373-380.
4. Rubello D., Girelli M.E., Casara D., Piccolo M., Perin A., Busnardo B. Usefulness of the combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest. 1990, 13:737-742.
5. Kumar A., Shah D.H., Shrihari U., Dandekar S.R., Vijayan U., Sharm S.M. Significance of antithyroglobulin autoantibodies in differentiated thyroid carcinoma. Thyroid. 1994, 4:199-202.
6. Spencer C.A., Takeuchi M., Kazarosyan M., Wang C.C., Guttler R.B., Singer P.A., et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1998, 83:1121-1127.
7. Hjiyiannakis P., Mundy J., Harmer C. Thyroglobulin antibodies in differentiated thyroid cancer. Clin Oncol. 1999, 11:240-244.
8. Rubello D., Casara D., Girelli M.E., Piccolo M., Busnardo B. Clinical meaning of circulating antithyroglobulin antibodies in differentiated thyroid cancer: a prospective study. J Nucl Med. 1992, 33:1478-1480.
9. Chung J.K., Park Y.J., Kim T.Y., So Y., Kim S.K., Park D.J., et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol. 2002, 57:215-221.
10. Phan H.T., Jager P.L., Van der Wal J.E., Sluiter W.J., Plukker J.T.M., Dierckx R.A., et al. The follow-up of patients with CDT and undetectable Tg and AbTg during ablation. Eur J Endocrinol. 2008, 158:77-83.
11. Franco Baux J., Borrego Dorado I., Gómez Camarero P., Rodríguez Rodríguez J.R., Vázquez Albertino R., Navarro González E., et al. PET-FDG in the follow-up of the differentiated thyroid cancer. Rev Esp Med Nucl. 2005, 24:5-13.
12. 131I Whole body scanning of patients with differentiated thyroid cancer. Endocrinol Nutr. 2008, 55:117-122.
13. Lind P., Kohlfurst S. Respectives Roles of thyroglobulin, radioiodine Imaging and Positron Emission Tomography in the Assessment of Thyroid Cancer. Semin Nucl Med. 2006, 36:194-205.
14. 131I whole-body scans and elevated thyroglobulin levels: a possible course. Rev Esp Med Nucl. 2007, 26:138-145.
15. Bogsrud T.V., Karantanis D., Nathan M.A., Mullan B.P., Wiseman G.A., Hay I.D., et al. FDG-PET in the management of patients with well differentiated thyroid carcinoma and positive thyroglobulin autoantibodies. Abstrac in " Ann Congress EAMN 2007" (Copenhagen). Eur J Nucl Med. 2007, 34:S122.
16. Chiovato L., Latrofa F., Braverman L., Paccini F., Capezzone M., Masserini L., et al. Disapperance of Humoral thyroid autoinmunity after complete Removal of thyroid Antigens. Ann Intern Med. 2003, 139:346-351.
17. Cooper D., Doherty G.M., Haugen B.R., Kloos R., Lee S., Mandel S.J. Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules an Differenciated Thyroid Cancer. Thyroid. 2009, 19:1167-1200.
18. Borrego Dorado I., Vázquez Albertino R. A proposal for the rational use of the PET in oncology. Rev Esp Med Nucl. 2002, 21:163-173.
19. 131I scan. J Nucl Med. 2001, 42:71-76.
20. 131I scanning results after therapy. J Nucl Med. 2001, 42:1464-1469.
21. 18-fluorodexyglucose positron emission tomographyin the follow up of of diffenciated thyroid cancer. Eur J Nucl Med. 1996, 23:312-319.
22. Feine U, Lietnmayer R, Hanke JP, Held J, Worle H, Muller SW. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996;37:1468-72.